// App-Quantinova.ai

3698 : A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Researchers

Presenter

  • Leslie Popplewell

Principal Investigators

  • Paul Frankel

  • Tanya Siddiqi

  • Joel Conrad

  • Michelle Mott

  • Myo Htut

  • Auayporn Nademanee

  • Stephen J Forman

  • Liang Li

  • Mark Kirschbaum

Medical Centers

  • Division of Hematopoietic Stem Cell & Leukemia, City of Hope National Medical Center, Duarte, CA

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Diffuse large B-cell lymphoma

  • Waldenstrom’s macroglobulinemia

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Pulmonary embolism

  • B-Cell Non-Hodgkin Lymphoma

  • B cell lymphomas

  • Hypophosphatemic rickets

  • Thrombocytopenia

  • Hyperglycemia

  • Non‐Hodgkin Lymphoma

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

  • Syncope

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Vorinostat

  • tositumomab

  • Enoxaparin

  • Enoxaparin sodium

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved